Clinical Trial Update: Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection [Phase 2]

View source ↗

Summary

This Phase 2 study reports on the pharmacokinetics and safety of voriconazole in children aged 2 to 11 at high risk for systemic fungal infections, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Candidemia
• Candidiasis

Drugs mentioned

• VFEND (Voriconazole)

Snippet

Sponsor: Pfizer | Conditions: Candidiasis, Candidemia | Phase 2 | Status: COMPLETED | Results posted: 2011-01-25